Advertisement

The Use of Positron Emission Tomography (PET) in the Staging/Evaluation, Treatment, and Follow-Up of Patients With Lung Cancer: A Critical Review

      The availability of clinical positron emission tomography (PET) is increasing rapidly in the developed world (
      • Siegel B.A.
      • Dehdashti F.
      Oncologic PET/CT: Current status and controversies.
      ). This article reviews the role of PET scanning in lung cancer, emphasizing issues relevant to the radiation oncology community. Fused PET/computed tomography (CT) images, acquired using modern hybrid scanners, are the most powerful means currently available for imaging lung cancer and are more accurate than either PET and CT scans acquired separately (
      • Freudenberg L.S.
      • Rosenbaum S.J.
      • Beyer T.
      • et al.
      PET versus PET/CT dual-modality imaging in evaluation of lung cancer.
      ). Advantages of PET/CT include greater precision in localizing suspicious tracer uptake, improving both sensitivity and specificity, more accurate quantification of tracer uptake, and improved radiation therapy (RT) planning. Although stand-alone PET is being superseded by PET/CT, many older studies remain relevant because extensive data are not yet available for hybrid scanners.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel B.A.
        • Dehdashti F.
        Oncologic PET/CT: Current status and controversies.
        Eur Radiol. 2005; 15: D127-D132
        • Freudenberg L.S.
        • Rosenbaum S.J.
        • Beyer T.
        • et al.
        PET versus PET/CT dual-modality imaging in evaluation of lung cancer.
        Radiol Clin North Am. 2007; 45 (v): 639-644
        • Chen W.
        • Cloughesy T.
        • Kamdar N.
        • et al.
        Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG.
        J Nucl Med. 2005; 46: 945-952
        • Rajendran J.G.
        • Krohn K.A.
        Imaging hypoxia and angiogenesis in tumors.
        Radiol Clin North Am. 2005; 43: 169-187
        • Park S.J.
        • Ionascu D.
        • Killoran J.
        • et al.
        Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images.
        Phys Med Biol. 2008; 53: 3661-3679
        • Berghmans T.
        • Dusart M.
        • Paesmans M.
        • et al.
        Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
        J Thorac Oncol. 2008; 3: 6-12
        • Gould M.K.
        • Maclean C.C.
        • Kuschner W.G.
        • et al.
        Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis.
        JAMA. 2001; 285: 914-924
        • Nomori H.
        • Watanabe K.
        • Ohtsuka T.
        • et al.
        Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size.
        Ann Thorac Surg. 2005; 79 (discussion 989): 984-988
        • Toloza E.M.
        • Harpole L.
        • McCrory D.C.
        Noninvasive staging of non–small cell lung cancer: A review of the current evidence.
        Chest. 2003; 123: 137S-146S
        • Dwamena B.A.
        • Sonnad S.S.
        • Angobaldo J.O.
        • et al.
        Metastases from non–small cell lung cancer: Mediastinal staging in the 1990s—meta-analytic comparison of PET and CT.
        Radiology. 1999; 213: 530-536
        • Gould M.K.
        • Kuschner W.G.
        • Rydzak C.E.
        • et al.
        Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis.
        Ann Intern Med. 2003; 139: 879-892
        • Hellwig D.
        • Ukena D.
        • Paulsen F.
        • et al.
        [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
        Pneumologie. 2001; 55: 367-377
        • Silvestri G.A.
        • Gould M.K.
        • Margolis M.L.
        • et al.
        Noninvasive staging of non–small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition).
        Chest. 2007; 132: 178S-201S
        • Kernstine K.H.
        • McLaughlin K.A.
        • Menda Y.
        • et al.
        Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?.
        Ann Thorac Surg. 2002; 73 (discussion 401–392): 394-401
        • Reed C.E.
        • Harpole D.H.
        • Posther K.E.
        • et al.
        Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non–small cell lung cancer.
        J Thorac Cardiovasc Surg. 2003; 126: 1943-1951
        • Graeter T.P.
        • Hellwig D.
        • Hoffmann K.
        • et al.
        Mediastinal lymph node staging in suspected lung cancer: Comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy.
        Ann Thorac Surg. 2003; 75 (discussion 235–236): 231-235
        • van Tinteren H.
        • Hoekstra O.S.
        • Smit E.F.
        • et al.
        Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial.
        Lancet. 2002; 359: 1388-1393
        • Viney R.C.
        • Boyer M.J.
        • King M.T.
        • et al.
        Randomized controlled trial of the role of positron emission tomography in the management of Stage I and II non-small-cell lung cancer.
        J Clin Oncol. 2004; 22: 2357-2362
        • Marom E.M.
        • McAdams H.P.
        • Erasmus J.J.
        • et al.
        Staging non–small cell lung cancer with whole-body PET.
        Radiology. 1999; 212: 803-809
        • Yun M.
        • Kim W.
        • Alnafisi N.
        • et al.
        18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
        J Nucl Med. 2001; 42: 1795-1799
        • MacManus M.P.
        • Hicks R.J.
        • Matthews J.P.
        • et al.
        High rate of detection of unsuspected distant metastases by pet in apparent Stage III non-small-cell lung cancer: implications for radical radiation therapy.
        Int J Radiat Oncol Biol Phys. 2001; 50: 287-293
        • MacManus M.R.
        • Hicks R.
        • Fisher R.
        • et al.
        FDG-PET-detected extracranial metastasis in patients with non–small cell lung cancer undergoing staging for surgery or radical radiotherapy—survival correlates with metastatic disease burden.
        Acta Oncol. 2003; 42: 48-54
        • Eschmann S.M.
        • Friedel G.
        • Paulsen F.
        • et al.
        FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
        Eur J Nucl Med Mol Imaging. 2002; 29: 804-808
        • Marom E.M.
        • Bruzzi J.F.
        • Truong M.T.
        Extrathoracic PET/CT findings in thoracic malignancies.
        J Thorac Imaging. 2006; 21: 154-166
        • Mac Manus M.P.
        • Hicks R.J.
        • Ball D.L.
        • et al.
        F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment.
        Cancer. 2001; 92: 886-895
        • Mac Manus M.P.
        • Wong K.
        • Hicks R.J.
        • et al.
        Early mortality after radical radiotherapy for non-small-cell lung cancer: Comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center.
        Int J Radiat Oncol Biol Phys. 2002; 52: 351-361
        • Kiffer J.D.
        • Berlangieri S.U.
        • Scott A.M.
        • et al.
        The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer.
        Lung Cancer. 1998; 19: 167-177
        • Munley M.T.
        • Marks L.B.
        • Scarfone C.
        • et al.
        Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects.
        Lung Cancer. 1999; 23: 105-114
        • Nestle U.
        • Walter K.
        • Schmidt S.
        • et al.
        18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis.
        Int J Radiat Oncol Biol Phys. 1999; 44: 593-597
        • Vanuytsel L.J.
        • Vansteenkiste J.F.
        • Stroobants S.G.
        • et al.
        The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non–small cell lung cancer.
        Radiother Oncol. 2000; 55: 317-324
        • Giraud P.
        • De Rycke Y.
        • Minet P.
        • et al.
        [Estimation of the probability of mediastinal involvement: A statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy in non-small-cell lung cancer?].
        Cancer Radiother. 2001; 5: 725-736
        • Caldwell C.B.
        • Mah K.
        • Ung Y.C.
        • et al.
        Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion.
        Int J Radiat Oncol Biol Phys. 2001; 51: 923-931
        • Mah K.
        • Caldwell C.B.
        • Ung Y.C.
        • et al.
        The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study.
        Int J Radiat Oncol Biol Phys. 2002; 52: 339-350
        • Erdi Y.E.
        • Rosenzweig K.
        • Erdi A.K.
        • et al.
        Radiotherapy treatment planning for patients with non–small cell lung cancer using positron emission tomography (PET).
        Radiother Oncol. 2002; 62: 51-60
        • Bradley J.
        • Thorstad W.L.
        • Mutic S.
        • et al.
        Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2004; 59: 78-86
        • Messa C.
        • Ceresoli G.L.
        • Rizzo G.
        • et al.
        Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
        Q J Nucl Med Mol Imaging. 2005; 49: 259-266
        • van Der Wel A.
        • Nijsten S.
        • Hochstenbag M.
        • et al.
        Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: A modeling study.
        Int J Radiat Oncol Biol Phys. 2005; 61: 649-655
        • Ashamalla H.
        • Rafla S.
        • Parikh K.
        • et al.
        The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1016-1023
        • Deniaud-Alexandre E.
        • Touboul E.
        • Lerouge D.
        • et al.
        Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1432-1441
        • Remonnay R.
        • Morelle M.
        • Pommier P.
        • et al.
        Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making.
        Int J Technol Assess Health Care. 2008; 24: 212-220
        • van Baardwijk A.
        • Bosmans G.
        • Boersma L.
        • et al.
        PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
        Int J Radiat Oncol Biol Phys. 2007; 68: 771-778
        • Nestle U.
        • Kremp S.
        • Schaefer-Schuler A.
        • et al.
        Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non–small cell lung cancer.
        J Nucl Med. 2005; 46: 1342-1348
        • Stroom J.
        • Blaauwgeers H.
        • van Baardwijk A.
        • et al.
        Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors.
        Int J Radiat Oncol Biol Phys. 2007; 69: 267-275
        • Werner-Wasik M.
        • Xiao Y.
        • Pequignot E.
        • et al.
        Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
        Int J Radiat Oncol Biol Phys. 2001; 51: 56-61
        • Lever A.M.
        • Henderson D.
        • Ellis D.A.
        • et al.
        Radiation fibrosis mimicking local recurrence in small cell carcinoma of the bronchus.
        Br J Radiol. 1984; 57: 178-180
        • Mac Manus M.P.
        • Hicks R.J.
        • Matthews J.P.
        • et al.
        Positron emission tomography is superior to CT scanning for response-assessment after radical radiotherapy/chemoradiotherapy in patients with non-small cell lung cancer.
        J Clin Oncol. 2003; 21: 1285-1292
        • Bury T.
        • Corhay J.L.
        • Duysinx B.
        • et al.
        Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
        Eur Respir J. 1999; 14: 1376-1380
        • Mac Manus M.P.
        • Hicks R.J.
        • Matthews J.P.
        • et al.
        Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non–small cell lung cancer correlates with patterns of failure.
        Lung Cancer. 2005; 49: 95-108
        • Hicks R.J.
        • Mac Manus M.P.
        • Matthews J.P.
        • et al.
        Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.
        Int J Radiat Oncol Biol Phys. 2004; 60: 412-418
        • Akhurst T.
        • Downey R.J.
        • Ginsberg M.S.
        • et al.
        An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.
        Ann Thorac Surg. 2002; 73 (discussion 264–266): 259-264
        • Choi N.C.
        • Fischman A.J.
        • Niemierko A.
        • et al.
        Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2002; 54: 1024-1035
        • Dooms C.
        • Verbeken E.
        • Stroobants S.
        • et al.
        Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
        J Clin Oncol. 2008; 26: 1128-1134
        • Hoekstra C.J.
        • Hoekstra O.S.
        • Stroobants S.G.
        • et al.
        Methods to monitor response to chemotherapy in non–small cell lung cancer with 18F-FDG PET.
        J Nucl Med. 2002; 43: 1304-1309
        • Kong F.M.
        • Frey K.A.
        • Quint L.E.
        • et al.
        A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
        J Clin Oncol. 2007; 25: 3116-3123
        • Hicks R.J.
        • Kalff V.
        • MacManus M.P.
        • et al.
        The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification.
        J Nucl Med. 2001; 42: 1605-1613

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.